Yanong Wang

机构：Shanghai Medical College of Fudan University, Chinese Academy of Sciences, Peking University, Interface (United States), ShanghaiTech University, Suzhou Institute of Nano-tech and Nano-bionics, Fudan University Shanghai Cancer Center, Peking University Cancer Hospital, NanoBio (United States) · ORCID：0000-0001-8454-2701

发表论文 73 篇 · 总被引 3263 次 · h-index 30

代表论文

• Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial (2021 · The Lancet Oncology · 被引 449)
• Genetic risk, incident gastric cancer, and healthy lifestyle: a meta-analysis of genome-wide association studies and prospective cohort study (2020 · The Lancet Oncology · 被引 260)
• Analysis of lymph node metastasis in early gastric cancer: a single institutional experience from China (2020 · World Journal of Surgical Oncology · 被引 79)
• Meta-analysis of genome-wide association studies and functional assays decipher susceptibility genes for gastric cancer in Chinese populations (2019 · Gut · 被引 74)
• Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial (2025 · The Lancet Oncology · 被引 56)
• RPS15A promotes gastric cancer progression via activation of the Akt/IKK‐β/NF‐κB signalling pathway (2019 · Journal of Cellular and Molecular Medicine · 被引 50)